Is XELOX Equivalent to FOLFOX or Other Continuous-Infusion 5-Fluorouracil Chemotherapy in Metastatic Colorectal Cancer?

Clinical Colorectal Cancer - Tập 7 - Trang 206-211 - 2008
Jean-Yves Douillard1, Jaafar Bennouna1, Helene Senellart1
1Department of Medical Oncology, Centre R. Gauducheau, St. Herblain, France

Tài liệu tham khảo

Thirion, 2004, Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. Meta-Analysis Group in Cancer, J Clin Oncol, 18, 3766

Meta-Analysis Group in Cancer, 1998, Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors, J Clin Oncol, 16, 3537, 10.1200/JCO.1998.16.11.3537

De Gramont, 2000, Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer, J Clin Oncol, 18, 2938, 10.1200/JCO.2000.18.16.2938

Douillard, 2000, Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial, Lancet, 355, 1041, 10.1016/S0140-6736(00)02034-1

Tournigand, 2004, FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study, J Clin Oncol, 22, 229, 10.1200/JCO.2004.05.113

Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer, N Engl J Med, 350, 2335, 10.1056/NEJMoa032691

Van Cutsem, 2007, CRYSTAL, a ran-domized phase III trial of cetuximab plus FOLFIRI vs. FOLFIRI in first-line metastatic colorectal cancer (mCRC), Eur J Cancer, 5, 235, 10.1016/S1359-6349(07)70929-1

Van Cutsem, 2001, Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study, J Clin Oncol, 19, 4097, 10.1200/JCO.2001.19.21.4097

Van Hoff, 2001, Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study, J Clin Oncol, 19, 2282, 10.1200/JCO.2001.19.8.2282

Welles, 2004, Preliminary results of a randomized study of the safety and tolerability of three oxaliplatinbased regimens as first-line treatment for advanced colorectal cancer (CRC) (“TREE” study), Proc Am Soc Clin Oncol, 23, 254

Cassidy J, Clarke S, Diaz-Rubio E. First efficacy and safety results from XELOX-1/NO16966, a randomized 2x2 factorial phase III trial of XELOX vs. FOLFOX4 + bevacizumab or placebo in first-line metastatic colorectal cancer (MCRC). Presented at: 2006 Annual Meeting of the European Society of Medical Oncology; September 29-October 3, 2006; Istanbul, Turkey. Abstract LBA 3.

Ducreux, 2007, Efficacy and safety findings from a randomized phase III study of capecitabine+oxaliplatin vs. infusional 5-FU/acid folinic+oxaliplatin (FOLFOX6) as first-line treatment for metastatic colorectal cancer (MCRC), J Clin Oncol, 25, 170s

Diaz-Rubio, 2007, Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumor trial, J Clin Oncol, 25, 4224, 10.1200/JCO.2006.09.8467

Porschen, 2007, Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO colorectal study group, J Clin Oncol, 25, 4217, 10.1200/JCO.2006.09.2684

Comella, 2007, Capecitabine or Fluorouracil/Folinic Acid IV Bolus plus Eloxatin Evaluation (COFFEE trial) in metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Group (SICOG) phase III trial 0401, Eur J Cancer, 5, 248, 10.1016/S1359-6349(07)70972-2

Hochster, 2006, Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final results of the TREE-study, J Clin Oncol, 24, 148s

Berry, 2007, Preliminary efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI and fluoropyrimidines for mCRC: first BEAT trial, Eur J Cancer, 5, 241, 10.1016/S1359-6349(07)70948-5

Arkenau H, Arnold D, Diaz-Rubio E, et al. Capecitabine and oxaliplatin as first-line treatment in patients with metastatic colorectal cancer (MCRC): a combined analysis of randomized phase II-III trials. Presented at: 2008 American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, FL. Abstract 342.

Twelves, 2006, A randomized cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer, Ann Oncol, 17, 239, 10.1093/annonc/mdj023

Hebbar, 2007, Safety and quality of life (QoL) findings from a randomized phase III study of capecitabine+oxaliplatin (XELOX) vs. infusional 5-FU/folinic acid (FA)+oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer (MCRC), J Clin Oncol, 25, 188s

Perrocheau, 2007, Cost-minimization analysis of a phase III study of capecitabine+oxaliplatin vs. infusional 5-FU/folinic acid (FA)+oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer (MCRC) in the French setting, J Clin Oncol, 25, 184s

Mayer, 2007, Should Capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?, J Clin Oncol, 27, 4164

Cassidy, 2006, Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial, Br J Cancer, 94, 1122, 10.1038/sj.bjc.6603059

Chu, 2008, Pharmacoeconomic benefits of capecitabinebased chemotherapy in metastatic colorectal cancer, J Clin Oncol, 26, 2224, 10.1200/JCO.2008.16.2826

Thông tin
Thông tin xuất bản

Clinical Colorectal Cancer

Tập 7

206-211

Thông tin tác giả